Pharmacokinetics of the proteasome inhibitor bortezomib (VELCADE™) in male cynomolgus monkeys.

被引：0

作者：

Nix, D ^{[1
]}

Milton, M ^{[1
]}

Pligavko, C ^{[1
]}

Nagaraja, N ^{[1
]}

Huang, R ^{[1
]}

Miwa, G ^{[1
]}

机构：

[1] Millennium Pharmaceut Inc, Cambridge, MA USA

来源：

CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：6263S / 6263S

页数：1

共 50 条

[41] Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects
Shahshahan, Mohammad A.
Beckley, Maureen N.
Jazirehi, Ali R.
[J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2011, 1 (07): : 913 - 924
[42] Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)
Serra Kamer
Qing Ren
Adam P. Dicker
[J]. Archives of Gynecology and Obstetrics, 2009, 279 : 41 - 46
[43] Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)
Kamer, Serra
Ren, Qing
Dicker, Adam P.
[J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2009, 279 (01) : 41 - 46
[44] Phase II trial of the proteasome inhibitor bortezomib (PS-341, Velcade™) in patients with relapsed/refractory multiple myeloma
不详
[J]. CLINICAL LYMPHOMA, 2003, 4 (01): : 11 - 12
[45] The effect of proteasome inhibition with bortezomib(Velcade™) in B cell lymphoma cell lines
Strauss, SJ
Liu, W
Maharaj, L
Shringarpure, R
Anderson, C
Schenkein, D
Lister, TA
Joel, SP
[J]. BRITISH JOURNAL OF CANCER, 2003, 88 : S65 - S65
[46] SB-462795, a cathepsin inhibitor, prevents the loss of bone mass at several sites in ovariectomized cynomolgus monkeys.
Stroup, G
Jerome, C
Yamashita, DS
Kumar, S
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S142 - S142
[47] Proteasome inhibitor, bortezomib, for myeloma and lymphoma
Tobinai, Kensei
[J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (05) : 318 - 326
[48] Proteasome inhibitor, bortezomib, for myeloma and lymphoma
Kensei Tobinai
[J]. International Journal of Clinical Oncology, 2007, 12 : 318 - 326
[49] The resistance mechanisms of proteasome inhibitor bortezomib
Lü S.
Wang J.
[J]. Biomarker Research, 1 (1)
[50] Histomorphometric and biochemical evidence for a cortical bone-forming effect of a cathepsin K inhibitor in ovariectomized cynomolgus monkeys.
Stroup, G
Jerome, C
Yamashita, DS
Kumar, S
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S80 - S80

← 1 2 3 4 5 →